Therefore, therapeutic strategies for SSc and some other fibrotic disorders may be designed by blockade of HSP47 expression, the downstream effector of TGF-β signaling, to ameliorate fibrosis. The gene discussed is TGFB1; the disease is systemic sclerosis.